1-methyl-4-oxo-N-(2-(trifluoromethyl)biphenyl-4-yl)-7-vinyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide | 1351945-25-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methyl-4-oxo-N-(2-(trifluoromethyl)biphenyl-4-yl)-7-vinyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
• CAS: 1351945-25-9
• 化学式: C₂₅H₁₈F₃N₃O₂
• 分子量: 449.432
• InChiKey: HQKVGHBLZYSNEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.51
• 重原子数：
  33.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  63.99
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  1-methyl-4-oxo-N-(2-(trifluoromethyl)biphenyl-4-yl)-7-vinyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide 在 sodium periodate 、 四氧化锇 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 以97%的产率得到7-formyl-1-methyl-4-oxo-N-(2-(trifluoromethyl)biphenyl-4-yl)-1,4-dihydro-1,6-naphthyridine-3-carboxamide
  参考文献：
  名称：

  Optimization of a Potent, Orally Active S1P₁ Agonist Containing a Quinolinone Core

  摘要：

  The optimization of a series of SIP, agonists with limited activity against S1P(3) is reported. A polar headgroup was used to improve the physicochemical and pharmacokinetic parameters of lead quinolinone 6. When dosed orally at 1 and 3 mg/kg, the azahydroxymethyl analogue 22 achieved statistically significant lowering of circulating blood lymphocytes 24 h postdose. In rats, a dose-proportional increase in exposure was measured when 22 was dosed orally at 2 and 100 mg/kg.

  DOI：

  10.1021/ml200252b
• 作为产物：
  描述：

  7-chloro-1-methyl-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid 在 二(三叔丁基膦)钯 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 cesium fluoride 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.16h， 生成 1-methyl-4-oxo-N-(2-(trifluoromethyl)biphenyl-4-yl)-7-vinyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
  参考文献：
  名称：

  Optimization of a Potent, Orally Active S1P₁ Agonist Containing a Quinolinone Core

  摘要：

  The optimization of a series of SIP, agonists with limited activity against S1P(3) is reported. A polar headgroup was used to improve the physicochemical and pharmacokinetic parameters of lead quinolinone 6. When dosed orally at 1 and 3 mg/kg, the azahydroxymethyl analogue 22 achieved statistically significant lowering of circulating blood lymphocytes 24 h postdose. In rats, a dose-proportional increase in exposure was measured when 22 was dosed orally at 2 and 100 mg/kg.

  DOI：

  10.1021/ml200252b